Growth Metrics

Esperion Therapeutics (ESPR) Other Working Capital Changes (2016 - 2026)

Esperion Therapeutics filings provide 8 years of Other Working Capital Changes readings, the most recent being $3.8 million for Q4 2025.

  • On a quarterly basis, Other Working Capital Changes rose 137.19% to $3.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $26.0 million, a N/A change, with the full-year FY2025 number at $26.0 million, changed N/A from a year prior.
  • Other Working Capital Changes hit $3.8 million in Q4 2025 for Esperion Therapeutics, down from $14.7 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $23.5 million in Q4 2023 to a low of -$12.4 million in Q2 2023.
  • Median Other Working Capital Changes over the past 5 years was $887500.0 (2021), compared with a mean of $2.6 million.
  • The widest YoY moves for Other Working Capital Changes: up 4627.22% in 2023, down 3836.94% in 2023.
  • Esperion Therapeutics' Other Working Capital Changes stood at $5.8 million in 2021, then crashed by 109.01% to -$518000.0 in 2022, then skyrocketed by 4627.22% to $23.5 million in 2023, then plummeted by 143.55% to -$10.2 million in 2024, then soared by 137.19% to $3.8 million in 2025.
  • The last three reported values for Other Working Capital Changes were $3.8 million (Q4 2025), $14.7 million (Q3 2025), and $11.4 million (Q2 2025) per Business Quant data.